Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPRT1 | P00492 | 10/20 | 1.00 |
| ▸ | PNP | P00491 | 11/20 | 0.94 |
| ▸ | USP2 | O75604 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | EDNRA | P25101 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
| ▸ | RECQL | P46063 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | HBB | P68871 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | POLG | P54098 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23859843 | 0.93 | HPRT1 (1.00) | HPRT1PNPUSP2TSHREDNRA | |
| SCHEMBL13805623 | 0.91 | HPRT1 (0.84) | HPRT1PNPUSP2TSHREDNRA | |
| SCHEMBL9621638 | 0.88 | HPRT1 (0.78) | HPRT1PNPUSP2TSHREDNRA | |
| SCHEMBL8896276 | 0.88 | HPRT1 (0.81) | HPRT1PNPUSP2TSHREDNRA | |
| Acyclovir SCHEMBL145606 | 0.87 | PNP (0.91) | HPRT1PNPUSP2TSHREDNRA | |
| Acyclovir SCHEMBL543440 | 0.87 | PNP (0.91) | HPRT1PNPUSP2TSHREDNRA | |
| Acyclovir SCHEMBL23440044 | 0.87 | PNP (0.91) | HPRT1PNPUSP2TSHREDNRA | |
| Acyclovir SCHEMBL145614 | 0.87 | PNP (0.91) | HPRT1PNPUSP2TSHREDNRA | |
| Acyclovir SCHEMBL8388395 | 0.87 | PNP (0.84) | HPRT1PNPUSP2TSHREDNRA | |
| SCHEMBL8898386 | 0.87 | HPRT1 (0.80) | HPRT1PNPUSP2TSHREDNRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2012799-B1 | METABOLICALLY STABLE ALKOXYALKYL ESTERS OF ANTIVIRAL OR ANTIPROLIFERATIVE PHOSPHONATES, NUCLEOSIDE PHOSPHONATES AND NUCLEOSIDE PHOSPHATES | CHIMERIX INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-8710030-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-04-29 | — | — | US | disclosed |
| US-20130045950-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-02-21 | — | — | US | disclosed |
| US-8193167-B2 | Pharmacologically active agents containing esterified phosphonates and methods for use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-05 | — | — | US | disclosed |
| US-8008308-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-30 | — | — | US | disclosed |
| US-7994143-B2 | Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates | CHIMERIX, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20100273742-A1 | Pharmacologically Active Agents Containing Esterified Phosphonates and Methods for Use Thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-10-28 | — | — | US | disclosed |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | CHIMERIX, INC. (US) | 2010-09-30 | — | — | US | disclosed |
| US-7790703-B2 | New phosphonate ester derivatives of purine or pyrimidine antivirals; side effect reduction, less toxic, bioavailability | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100173870-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2010-07-08 | — | — | US | disclosed |
| US-5047533-A | Viricides | SRI INTERNATIONAL (US) | 1991-09-10 | — | — | US | disclosed |
| EP-0309491-A1 | ANTIVIRAL AGENTS | SRI INTERNATIONAL (US) | 1989-04-05 | — | — | EP | disclosed |
| EP-0145739-B1 | NOVEL ANTIVIRAL AGENTS | SRI INTERNATIONAL (US) | 1989-02-08 | — | — | EP | disclosed |
| WO-1988005438-A1 | ANTIVIRAL AGENTS | SRI INTERNATIONAL (US) | 1988-07-28 | — | — | WO | disclosed |
| EP-0274025-A2 | Novel antiviral agents | SRI INTERNATIONAL (US) | 1988-07-13 | — | — | EP | disclosed |
| EP-0273169-A2 | Novel antiviral agents | SRI INTERNATIONAL (US) | 1988-07-06 | — | — | EP | disclosed |
| US-4755516-A | Antiviral compounds | MERCK & CO., INC. (US) | 1988-07-05 | — | — | US | disclosed |
| EP-0272446-A1 | Novel antiviral agents | SRI INTERNATIONAL (US) | 1988-06-29 | — | — | EP | disclosed |
| EP-0173624-A2 | 4-(guanin-9-yl) butanals and antiviral compositions containing them | MERCK & CO. INC. (US) | 1986-03-05 | — | — | EP | disclosed |
| WO-1984004748-A2 | NOVEL ANTIVIRAL AGENTS | — | 1984-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045950-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | HPRT1 130/4885PNP 74/4885USP2 4514/4885 |
| US-20100249056-A1 | Metabolically Stable Alkoxyalkyl Esters of Antiviral or Antiproliferative Phosphonates, Nucleoside Phosphonates and Nucleoside Phosphates | PNP, TYMP, ENPP1 | HPRT1 183/4885PNP 1/4885USP2 4216/4885 |
| US-20100273742-A1 | Pharmacologically Active Agents Containing Esterified Phosphonates and Methods for Use Thereof | PHPT1, PPIP5K2, PHOSPHO1 | HPRT1 881/4885PNP 30/4885USP2 3419/4885 |
| US-20100173870-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | HPRT1 130/4885PNP 74/4885USP2 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.